Answers are grounded in this paper and cite their sources.
Objectives The transition from inflammation to cancer (ICT) represents a pivotal precancerous phase common to various malignancies, necessitating advanced strategies for its accurate identification and integrated theranostic management. This review aims to comprehensively examine the evolving role of enzyme-targeted near-infrared (NIR) fluorescent probes in elucidating the complex molecular dynamics of ICT and to evaluate their translational potential for precision theranostics. Methods We synthesize recent literature on enzyme-activatable NIR agents, organizing the discussion around three themes: (i) molecular design principles of enzyme-targeted NIR probes, emphasizing dual capability in real-time imaging and therapeutic modulation; (ii) application of these probes across the ICT continuum, spanning inflammation-cancer interplay, metastatic microenvironment detection, and tumor-associated microenvironmental remodeling; and (iii) representative disease-specific trajectories and translational case studies. Results Enzyme-activatable NIR probes, including aggregation-induced emission-based systems, enable biomarker-specific detection with high sensitivity and provide multimodal diagnostic-therapeutic capability. Representative probes targeting COX-2, MMPs, ALP, HNE, and other stage-specific enzymes demonstrate feasibility for monitoring inflammation-to-cancer progression, while several platforms integrate photodynamic or photothermal therapy with real-time imaging feedback. Comparative analysis across disease models, including colitis-to-colorectal cancer and hepatitis-to-hepatocellular carcinoma, highlights both progress and persistent gaps in probe validation. Conclusions Enzyme-targeted NIR agents hold substantial promise for spatiotemporally precise ICT monitoring; however, translational hurdles including probe specificity, in vivo pharmacokinetics, and standardized clinical validation remain. We propose a multidisciplinary roadmap integrating nanotechnology, artificial intelligence, and multi-omics strategies to accelerate development of next-generation theranostic probes, facilitating translation of molecular understanding into personalized anti-cancer interventions.
No takes yet. Share an insight, caveat, or question.
Hu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: